Owlet（OWLT）株式概要
Owlet, Inc.は、米国、英国、および国際的にデジタル子育てソリューションを提供しています。 詳細
OWLT Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Owlet, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$5.79 |
| 52週高値 | US$16.94 |
| 52週安値 | US$4.19 |
| ベータ | 1.83 |
| 1ヶ月の変化 | 10.71% |
| 3ヶ月変化 | -48.67% |
| 1年変化 | 16.97% |
| 3年間の変化 | 59.07% |
| 5年間の変化 | -95.84% |
| IPOからの変化 | -95.74% |
最新ニュース
Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking Alpha
ナラティブの更新 • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Recent updates
Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking Alphaナラティブの更新 • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.ナラティブの更新 • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.ナラティブの更新 • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.ナラティブの更新 • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.ナラティブの更新 • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.ナラティブの更新 • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.
ナラティブの更新 • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.分析記事 • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...
ナラティブの更新 • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.ナラティブの更新 • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.ナラティブの更新 • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.分析記事 • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...ナラティブの更新 • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.ナラティブの更新 • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.分析記事 • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...ナラティブの更新 • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.分析記事 • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
新しいナラティブ • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.分析記事 • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...分析記事 • Jul 18
Investors Continue Waiting On Sidelines For Owlet, Inc. (NYSE:OWLT)
With a price-to-sales (or "P/S") ratio of 0.7x Owlet, Inc. ( NYSE:OWLT ) may be sending very bullish signals at the...株主還元
| OWLT | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 5.7% | 2.0% | 1.1% |
| 1Y | 17.0% | -17.9% | 28.7% |
業界別リターン: OWLT過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: OWLTは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。
価格変動
| OWLT volatility | |
|---|---|
| OWLT Average Weekly Movement | 15.4% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: OWLTの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: OWLTの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2012 | 111 | Kurt Workman | www.owletcare.com |
は、米国、英国、および海外でデジタル子育てソリューションを提供している。同社はデジタル育児プラットフォームを提供し、親にリアルタイムのデータと洞察を提供している。また、脈拍数、活動量、酸素レベル、睡眠パターンなどのバイタルサインを追跡するパルスオキシメトリー技術を搭載したウェアラブル乳児健康モニター「ドリームソックス」、呼吸器合胞体ウイルス、肺炎、気管支炎、クループなどの診断を受けた乳児を対象とした「ベビーサット」、親が子供を監視できる音声・ビデオモニター「ドリームサイト」などのソックスモニターを提供している。さらに、ドリーム・ソックスとドリーム・サイトを統合し、健康と安全のためのコネクテッド・システムを構築するドリーム・デュオ、赤ちゃんの発育、健康、睡眠の傾向を個別に把握できるサブスクリプション・サービスのOwlet360、布製アクセサリー・ソックスやOwletソックス・トラベル・ケースなどのアクセサリーも提供している。同社は2012年に設立され、ユタ州リーハイに本社を置いている。
Owlet, Inc. 基礎のまとめ
| OWLT 基礎統計学 | |
|---|---|
| 時価総額 | US$167.92m |
| 収益（TTM） | -US$47.74m |
| 売上高(TTM) | US$107.06m |
1.6x
P/Sレシオ-3.5x
PER（株価収益率OWLT は割高か？
公正価値と評価分析を参照収益と収入
| OWLT 損益計算書（TTM） | |
|---|---|
| 収益 | US$107.06m |
| 売上原価 | US$52.61m |
| 売上総利益 | US$54.45m |
| その他の費用 | US$102.19m |
| 収益 | -US$47.74m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.65 |
| グロス・マージン | 50.86% |
| 純利益率 | -44.60% |
| 有利子負債／自己資本比率 | 55.4% |
OWLT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 23:15 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Owlet, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |